Literature DB >> 34987087

The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.

Lauren M Lucas1, Vipasha Dwivedi1, Jared I Senfeld1, Richard L Cullum1, Christopher P Mill1, J Tyler Piazza1, Ianthe N Bryant1, Laura J Cook1, S Tyler Miller1, James H Lott1, Connor M Kelley1, Elizabeth L Knerr1, Jessica A Markham1, David P Kaufmann1, Megan A Jacobi1, Jianzhong Shen1, David J Riese2.   

Abstract

ERBB4 (HER4) is a member of the ERBB family of receptor tyrosine kinases, a family that includes the epidermal growth factor receptor (EGFR/ERBB1/HER1), ERBB2 (Neu/HER2), and ERBB3 (HER3). EGFR and ERBB2 are oncoproteins and validated targets for therapeutic intervention in a variety of solid tumors. In contrast, the role that ERBB4 plays in human malignancies is ambiguous. Thus, here we review the literature regarding ERBB4 function in human malignancies. We review the mechanisms of ERBB4 signaling with an emphasis on mechanisms of signaling specificity. In the context of this signaling specificity, we discuss the hypothesis that ERBB4 appears to function as a tumor suppressor protein and as an oncoprotein. Next, we review the literature that describes the role of ERBB4 in tumors of the bladder, liver, prostate, brain, colon, stomach, lung, bone, ovary, thyroid, hematopoietic tissues, pancreas, breast, skin, head, and neck. Whenever possible, we discuss the possibility that ERBB4 mutants function as biomarkers in these tumors. Finally, we discuss the potential roles of ERBB4 mutants in the staging of human tumors and how ERBB4 function may dictate the treatment of human tumors. SIGNIFICANCE STATEMENT: This articles reviews ERBB4 function in the context of the mechanistic model that ERBB4 homodimers function as tumor suppressors, whereas ERBB4-EGFR or ERBB4-ERBB2 heterodimers act as oncogenes. Thus, this review serves as a mechanistic framework for clinicians and scientists to consider the role of ERBB4 and ERBB4 mutants in staging and treating human tumors.
Copyright © 2022 by The Author(s).

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34987087     DOI: 10.1124/pharmrev.121.000381

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  2 in total

1.  Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies.

Authors:  Carmen Miano; Donatella Romaniello; Martina Mazzeschi; Alessandra Morselli; Silvia Da Pra; Francesca Sacchi; Chiara Bongiovanni; Michela Sgarzi; Elvira Pantano; Mattia Lauriola; Gabriele D'Uva
Journal:  Front Oncol       Date:  2022-05-18       Impact factor: 5.738

Review 2.  ErbB4 in the brain: Focus on high grade glioma.

Authors:  Jamie-Lee Pitcher; Naomi Alexander; Panimaya Jeffreena Miranda; Terrance G Johns
Journal:  Front Oncol       Date:  2022-08-31       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.